Cited 0 times in
Patients' self-management of adverse events and patient-reported outcomes in advanced renal cell carcinoma treated with targeted therapies: A prospective, longitudinal, observational study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 정병하 | - |
dc.date.accessioned | 2023-04-07T01:29:49Z | - |
dc.date.available | 2023-04-07T01:29:49Z | - |
dc.date.issued | 2022-12 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/193954 | - |
dc.description.abstract | Background: Early intervention to reduce the impact of adverse events (AEs) may improve patients' quality of life and enable optimal treatment duration. Methods: This nationwide, multicenter, prospective, longitudinal, 1-year observational study investigated patients' self-management of AEs associated with targeted therapy for advanced renal cell carcinoma (RCC) and explored corresponding outcomes, including treatment duration and patient-reported outcomes (PROs). Results: We enrolled 77 advanced RCC patients (mean age 62 years) treated with a first targeted therapy. 210 cases of seven AEs of interest (fatigue, hand-foot syndrome, oral mucosal inflammation, diarrhea, gastrointestinal symptoms, hypertension, and anorexia) were observed. Most AEs were mild to moderate. Overall, 63.4% of patients were identified as managing their AEs well, reporting numerically longer treatment duration and significantly higher PRO scores than patients identified as poor managers. Conclusions: Longer treatment duration and improved PROs were observed when advanced RCC patients managed targeted therapy-associated AEs well. Repeated education for consolidating AE self-management could be considered to enhance overall treatment outcomes. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Springer International Publishing | - |
dc.relation.isPartOf | JOURNAL OF PATIENT-REPORTED OUTCOMES | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Patients' self-management of adverse events and patient-reported outcomes in advanced renal cell carcinoma treated with targeted therapies: A prospective, longitudinal, observational study | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Urology (비뇨의학교실) | - |
dc.contributor.googleauthor | Sung-Hoo Hong | - |
dc.contributor.googleauthor | Ho Seok Chung | - |
dc.contributor.googleauthor | Ill-Young Seo | - |
dc.contributor.googleauthor | Tae Gyun Kwon | - |
dc.contributor.googleauthor | Hyeon Jeong | - |
dc.contributor.googleauthor | Jae-Il Chung | - |
dc.contributor.googleauthor | Seung Hyun Jeon | - |
dc.contributor.googleauthor | Jae Young Park | - |
dc.contributor.googleauthor | Hong Koo Ha | - |
dc.contributor.googleauthor | Byung-Ha Chung | - |
dc.contributor.googleauthor | Wan Song | - |
dc.contributor.googleauthor | Young-Joo Kim | - |
dc.contributor.googleauthor | Sang-Hee Kim | - |
dc.contributor.googleauthor | Jee-Sun Lee | - |
dc.contributor.googleauthor | Juneyoung Lee | - |
dc.contributor.googleauthor | Jinsoo Chung | - |
dc.identifier.doi | 10.1186/s41687-022-00532-0 | - |
dc.contributor.localId | A03607 | - |
dc.relation.journalcode | J04410 | - |
dc.identifier.eissn | 2509-8020 | - |
dc.identifier.pmid | 36525150 | - |
dc.subject.keyword | Carcinoma | - |
dc.subject.keyword | Molecular targeted therapy | - |
dc.subject.keyword | Patient reported outcome measures | - |
dc.subject.keyword | Renal cell | - |
dc.subject.keyword | Self-management | - |
dc.subject.keyword | Side effects and adverse reactions | - |
dc.contributor.alternativeName | Chung, Byung Ha | - |
dc.contributor.affiliatedAuthor | 정병하 | - |
dc.citation.volume | 6 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 125 | - |
dc.identifier.bibliographicCitation | JOURNAL OF PATIENT-REPORTED OUTCOMES, Vol.6(1) : 125, 2022-12 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.